BioMarin Pharmaceutical Inc. (BMRN) CEO J.J. Bienaime on Q4 2021 Results - Earnings Call Transcript

Feb. 23, 2022 9:18 PM ETBioMarin Pharmaceutical Inc. (BMRN) StockBMRN
SA Transcripts
153.96K Followers

Q4: 2022-02-23 Earnings Summary

EPS of $0.04 beats by $0.05
 | Revenue of $449.81M (-0.51% Y/Y) beats by $7.43M

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Q4 2021 Results Conference Call February 23, 2022 4:30 PM ET

Company Participants

Traci McCarty - Vice President of Investor Relations
J.J. Bienaime - Chairman and Chief Executive Officer
Jeff Ajer - Executive Vice President and Chief Commercial Officer
Hank Fuchs - President, Worldwide Research and Development
Greg Guyer - Executive Vice President and Chief Technical Officer
Brian Mueller - Executive Vice President, Chief Financial Officer

Conference Call Participants

Salveen Richter - Goldman Sachs
Cory Kasimov - JPMorgan
Ally Bratzel - Piper Sandler
Phil Nadeau - Cowen
Geoff Meacham - Bank of America
Gena Wang - Barclays
Kennen MacKay - RBC Capital Markets
Paul Matteis - Stifel
Joseph Schwartz - SVB Leerink
Avatar Jones - Morgan Stanley
Joel Beatty - Baird

Operator

Welcome to the BioMarin Fourth Quarter 2021 Financial Results Conference Call. Hosting the conference call today from BioMarin is Traci McCarty, Vice President of Investor Relations. Please go ahead, Traci.

Traci McCarty

Thank you, operator. Thank you all for joining us today. To remind you, this non-confidential presentation contains forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc., including expectations regarding BioMarin's financial performance, commercial products and potential future products in different areas of therapeutic research and development.

Results may differ materially depending on the progress of BioMarin's product programs, actions of regulatory authorities, availability of capital, future actions in the pharmaceutical market and developments by competitors and those factors detailed in BioMarin's filings with the Securities and Exchange Commission, such as 10-Q, 10-K and 8-K reports.

On the call today from BioMarin's management team are J.J. Bienaime, Chairman and Chief Executive Officer; Jeff Ajer, Executive Vice President and Chief Commercial Officer; Hank Fuchs, President, Worldwide Research and Development; Greg Guyer, Executive Vice President and Chief Technical Officer; and Brian Mueller, Executive Vice President and Chief Financial Officer.

Recommended For You

About BMRN Stock

SymbolLast Price% Chg
Market Cap
PE
Yield
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

More on BMRN